Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

Conditions:   Metastatic Breast Cancer;   Triple Negative Breast Cancer Intervention:   Drug: PMD-026 Sponsor:   Phoenix Molecular Designs Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials